10 Best Growth Stocks to Buy for the Next 20 Years

Market Overview - The S&P 500 and Dow have risen for nine consecutive months on a total return basis despite rising geopolitical tensions [2] - A potential 5% dip in the market is anticipated in the second half of February due to high optimism and put-to-call ratios, but the bull market remains intact with solid fundamentals [2] Technology Sector Insights - The market is experiencing indiscriminate selling, with a notable increase in short interest in the XLK (Tech ETF) reaching its highest level in years [3] - Software valuations are at their cheapest since 2013, presenting a buying opportunity, as the Carson Group has added to tech and software positions [3] Akebia Therapeutics Inc. (NASDAQ:AKBA) - Akebia reported total revenue of $58.8 million in Q3, with a net income of $540,000, recovering from a $20 million net loss in Q3 2024 [10] - The launch of its dialysis drug Vafseo generated lower-than-expected revenue of $14.3 million, but patient access expanded to 70,000 with over 700 active prescribers [10] - Management anticipates a temporary revenue dip in Q4 due to inventory adjustments but projects growth to resume in Q1 2026, focusing on its 2026 pipeline outlook [11] LiveRamp Holdings Inc. (NYSE:RAMP) - LiveRamp reported a revenue growth of 9% year-over-year to $212 million in FQ3 2026, exceeding expectations [14] - The company has formed a significant strategic partnership with Publicis and expanded its Data Marketplace to include AI models, positioning for double-digit growth in fiscal year 2027 [14] - Subscription net retention has compressed to 101%, and gross margins are expected to dip slightly, with a projected sequential increase in operating expenses of $15 million in FQ4 [15]